Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results (Q36866618)

16 August 2017

Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results (English)

1 reference

16 August 2017

1 reference

1 reference

Per Odin

1 reference

16 August 2017

Robert A Hauser

1 reference

16 August 2017

Hubert H Fernandez

1 reference

16 August 2017

Arvydas Vanagunas

1 reference

16 August 2017

Alberto J Espay

1 reference

16 August 2017

David G Standaert

1 reference

16 August 2017

Krai Chatamra

1 reference

16 August 2017

Janet Benesh

1 reference

16 August 2017

Yili Pritchett

1 reference

16 August 2017

Steven L Hass

1 reference

16 August 2017

Robert A Lenz

1 reference

16 August 2017

1 January 2013

1 reference

Parkinsonism and Related Disorders

16 August 2017

1 reference

inferred from page(s)

published in

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

339-345

1 reference

Levodopa–carbidopa intestinal gel for treatment of advanced Parkinson’s disease

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Levodopa: past, present, and future

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Role of homocysteine in the treatment of Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Minimizing endoscopic complications in enteral access

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Levodopa in the treatment of Parkinson's disease: current controversies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Complications of enteral access

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Treatment of Parkinsonism With Levodopa

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Continuous levodopa for advanced Parkinson's disease.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Parkinson's disease symptoms: the patient's perspective

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Neuropathy as a potential complication of levodopa use in Parkinson's disease

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

A randomized trial of deep-brain stimulation for Parkinson's disease

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Impact of the motor complications of Parkinson's disease on the quality of life

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3661282

Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility

4 September 2018

1 reference

12 December 2020

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group

1 reference

12 December 2020

A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia

1 reference

12 December 2020

Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease

1 reference

12 December 2020

The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport

1 reference

12 December 2020

10.1016/J.PARKRELDIS.2012.11.020

Identifiers

DOI

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

23287001

1 reference